Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...

The following is a summary of “Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR),” published in the October 2024 issue of Allergy and Immunology by Seys et al. Pivotal ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line ...

The following is a summary of “Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP,” published in the August 2024 issue of Allergy and Immunology by Bachert et al.

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...